[Tumor-regressive potency of soluble factors released from tumor-immune cells].
Liposome-encapsulated soluble factors, which were prepared from activated peritoneal exudate cells or spleen cells by stimulation with tumor-associated antigens and Con A, successfully regressed line 10 tumors transplanted into strain 2 guinea pigs. By intralesional administration of these soluble factors, a tumor-regressive potency of 40-50% was attained. No direct cytotoxic activity of these factors was indicated against line 10 tumor cells in vitro. It is therefore postulated that liposome-encapsulated soluble factors activate immune cells which have accumulated around tumor cells which eventually leads to regression tumor.
D000818:Animals; D000951:Antigens, Neoplasm / Q000494:pharmacology; D003208:Concanavalin A / Q000494:pharmacology; D005326:Fetal Proteins / Q000494:pharmacology; D006168:Guinea Pigs; D008081:Liposomes / Q000008:administration & dosage; D008222:Lymphokines / Q000276:immunology* / Q000627:therapeutic use; D009374:Neoplasms, Experimental / Q000276:immunology* / Q000628:therapy; D013154:Spleen / Q000166:cytology / Q000276:immunology; D013491:Suppressor Factors, Immunologic
D000951:Antigens, Neoplasm; D005326:Fetal Proteins; D008081:Liposomes; D008222:Lymphokines; D013491:Suppressor Factors, Immunologic; C013256:soluble immune response suppressor; C036269:tumor-associated fetal antigen, rat; D003208:Concanavalin A